• Pacira Biosciences escalated proxy fight with activist DOMA Perpetual ahead of June 9 annual meeting, urging holders to vote FOR board nominees Christopher Christie, Samit Hirawat, Thomas Wiggans on blue proxy card.
• Board attacked DOMA slate as unqualified, warning activist push for deep cost cuts, pipeline halt, CEO change, immediate sale process could undermine long-term strategy.
• Campaign leaned on Q1 2026 performance tied to 5x30 plan, citing revenue of 177 million, adjusted EBITDA of 40.2 million, cash and investments of 202 million.
• Pacira highlighted Q1 share repurchases of 50 million, retiring about 2,200,000 shares, positioning it as disciplined capital return alongside growth investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.